GH Research FY2024 EPS Forecast Lowered by HC Wainwright

GH Research PLC (NASDAQ:GHRS - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 EPS estimates for GH Research in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.80) for the year, down from their previous estimate of ($0.76). HC Wainwright currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research's Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($0.49) EPS.

Separately, Canaccord Genuity Group reduced their price objective on GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, November 18th.

GH Research Stock Up 9.4 %

Shares of NASDAQ:GHRS traded up $0.91 during trading on Wednesday, reaching $10.60. 170,976 shares of the company traded hands, compared to its average volume of 92,087. The firm has a fifty day simple moving average of $8.41 and a 200 day simple moving average of $8.90. GH Research has a 1-year low of $6.00 and a 1-year high of $14.99. The firm has a market cap of $551.52 million, a P/E ratio of -13.42 and a beta of 0.84.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. increased its holdings in GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,686,689 shares of the company's stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).